-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $35 Price Target

Benzinga·06/13/2025 10:50:49
Listen to the news
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $35 price target.